AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RGNX · NASDAQ · Biotechnology

REGENXBIO (RGNX)

Develops one-time AAV gene therapies while licensing its NAV vector platform.

$7.46

vs last close−0.69 (−8.47%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	29	22	16	22	24	21	89	21	30	30	6	108
Cost of revenue	12	16	8	15	12	6	3	9	62	6	11	1
Gross profit	17	7	7	8	12	15	86	12	−32	24	−5	107
	81	71	69	64	74	66	73	76	20	82	79	78
Research & development	58	51	51	45	54	50	53	56	56	60	57	56
	23	19	18	19	19	20	20	20	20	22	21	22
General & administrative	23	19	18	19	19	20	20	20	20	22	21	22
Other expenses	0	0	0	0	0	−4	0	0	−56	0	0	0
Operating income	−65	−64	−62	−56	−62	−51	12	−63	−52	−58	−83	29
	3	1	−2	3	2	0	−6	−8	−10	−10	−7	−7
Interest income	0	2	0	0	0	0	0	3	0	0	0	1
Interest expense	2	1	2	0	1	9	9	11	13	12	9	8
Other non-operating income	−5	−2	0	−3	−3	−10	−3	−3	−4	−3	−2	−1
Income before tax	−62	−63	−63	−53	−60	−51	6	−71	−62	−67	−90	23
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−62	−63	−63	−53	−60	−51	6	−71	−62	−67	−90	23
Net income	−62	−63	−63	−53	−60	−51	6	−71	−62	−67	−90	23
EPS, basic	−$1.41	−$1.43	−$1.38	−$1.05	−$1.17	−$1.01	$0.12	−$1.38	−$1.20	−$1.30	−$1.72	$0.43
EPS, diluted	−$1.41	−$1.43	−$1.38	−$1.05	−$1.17	−$1.01	$0.12	−$1.38	−$1.20	−$1.30	−$1.72	$0.43
Weighted average shares, basic	44	44	46	51	51	51	51	51	52	52	52	53
Weighted average shares, diluted	44	44	46	51	51	51	51	51	52	52	52	53
EBITDA	−56	−57	−57	−48	−55	−38	19	−56	−45	−51	−77	34
Depreciation & amortization	4	4	4	4	4	4	4	4	4	4	4	4
EBIT	−60	−62	−61	−53	−59	−42	15	−60	−49	−55	−81	31